Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–81.
Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013;24(2):454–62.
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419–37.
Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK, CI-PeriNomS Group. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). Qual Life Res. 2017;26(11):2999–3010.
Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, Aaronson NK, Satele DV, Mattar BI, Green NB, Loprinzi CL. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012;20(3):625–32.
Miaskowski C, Mastick J, Paul SM, Abrams G, Cheung S, Sabes JH, Kober KM, Schumacher M, Conley YP, Topp K, et al. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Surviv. 2018;12(2):234–45.
Tanay MAL, Armes J, Ream E. The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care. 2017;26(5):e12443.
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22(8):2261–9.
Robertson J, Raizer J, Hodges JS, Gradishar W, Allen JA. Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients. J Peripher Nerv Syst. 2018;23(2):129–33.
Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28(4):270–82.
Molassiotis A, Wengstrom Y, Kearney N. Symptom cluster patterns during the first year after diagnosis with cancer. J Pain Symptom Manag. 2010;39(5):847–58.
Yates P, Miaskowski C, Cataldo JK, Paul SM, Cooper BA, Alexander K, Aouizerat B, Dunn L, Ritchie C, McCarthy A, et al. Differences in composition of symptom clusters between older and younger oncology patients. J Pain Symptom Manag. 2015;49(6):1025–34.
Sullivan CW, Leutwyler H, Dunn LB, Cooper BA, Paul SM, Levine JD, Hammer M, Conley YP, Miaskowski CA. Stability of symptom clusters in patients with breast cancer receiving chemotherapy. J Pain Symptom Manag. 2018;55(1):39–55.
Sullivan CW, Leutwyler H, Dunn LB, Miaskowski C. A review of the literature on symptom clusters in studies that included oncology patients receiving primary or adjuvant chemotherapy. J Clin Nurs. 2018;27(3–4):516–45.
Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer. 2019;19(1):132.
Fayers P, Bottomley A, EORTC Quality of Life Group, Quality of Life Unit, European Organisation for Research and Treatment of Cancer. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur J Cancer. 2002;38(suppl 4):S125–33.
Shih CL, Chen CH, Sheu CF, Lang HC, Hsieh CL. Validating and improving the reliability of the EORTC qlq-c30 using a multidimensional Rasch model. Value Health. 2013;16(5):848–54.
Wan C, Meng Q, Yang Z, Tu X, Feng C, Tang X, Zhang C. Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer. Ann Oncol. 2008;19(12):2053–60.
Cheng HL, Molassiotis A. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx). Asia Pac J Clin Oncol. 2019;15(1):56–62.
Thomas BC, Waller A, Malhi RL, Fung T, Carlson LE, Groff SL, Bultz BD. A longitudinal analysis of symptom clusters in cancer patients and their sociodemographic predictors. J Pain Symptom Manag. 2014;47(3):566–78.
Aktas A, Walsh D, Rybicki L. Symptom clusters: myth or reality? Palliat Med. 2010;24(4):373–85.
Boyette-Davis JA, Eng C, Wang XS, Cleeland CS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Zhang H, Dougherty PM. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res. 2012;18(11):3180–7.
Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (alliance). J Clin Oncol. 2015;33(30):3416–22.
Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2018;110(2). https://doi.org/10.1093/jnci/djx140.
Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, Chen LM, Kober KM, Conley YP, Chesney M, et al. Chemotherapy-induced neuropathy in cancer survivors. J Pain Symptom Manag. 2017;54(2):204–218.e2.
Kandula T, Farrar MA, Kiernan MC, Krishnan AV, Goldstein D, Horvath L, Grimison P, Boyle F, Baron-Hay S, Park SB. Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clin Neurophysiol. 2017;128(7):1166–75.
Scaioli V, Caraceni A, Martini C, Curzi S, Capri G, Luca G. Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neuro-Oncol. 2006;77(1):79–87.
Chan CW, Cheng H, Au SK, Leung KT, Li YC, Wong KH, Molassiotis A. Living with chemotherapy-induced peripheral neuropathy: uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors. Eur J Oncol Nurs. 2018;36:135–41.
Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer. Gynecol Oncol. 2017;145(1):148–53.
Miaskowski C, Paul SM, Mastick J, Schumacher M, Conley YP, Smoot B, Abrams G, Kober KM, Cheung S, Henderson-Sabes J, et al. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy. Eur J Oncol Nurs. 2018;32:1–11.
Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56.
Kim HJ. Common factor analysis versus principal component analysis: choice for symptom cluster research. Asian Nurs Res. 2008;2(1):17–24.
Kim HJ, Abraham I, Malone PS. Analytical methods and issues for symptom cluster research in oncology. Curr Opin Support Palliat Care. 2013;7(1):45–53.
Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35(23):2604–12.
Yorke J, Lloyd-Williams M, Smith J, Blackhall F, Harle A, Warden J, Ellis J, Pilling M, Haines J, Luker K, et al. Management of the respiratory distress symptom cluster in lung cancer: a randomized controlled feasibility trial. Support Care Cancer. 2015;23(11):3373–84.